LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Latigo Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 3, 2026
$14.30+0.30 (+2.14%)
Close on Oct 19, 2026
- Market cap
- $13.37M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
−$3.95 (−21.64%)since Aug 7, 2026
Weekly closes, adjusted for splits, on a log scale. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $13.37M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Book value per share
- -$295.26
- Diluted shares
- 1M
Two years at a glance
Fiscal years 2024 to 2025, USD
Reported period